Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EU Panel Backs Approval of Takeda’s Vedolizumab
March 25, 2014
- Sanofi Now Reconciled with All 3 Generic Makers over Allegra Patent
March 25, 2014
- Chugai to Join High-Quality Protein Crystal Growth Experiment in Kibo Space Lab
March 24, 2014
- OrphanPacific Voluntarily Recalls Buphenyl Tablets
March 24, 2014
- Hospira Voluntarily Recalls 9 Generic Anticancer Agents Due to Incomplete Labeling
March 24, 2014
- Maruho Files NDA for Acne Drug in Japan
March 20, 2014
- Astellas Seeks US Approval for Additional Indication of Enzalutamide
March 20, 2014
- Astellas, Daiichi Sankyo Hook Up in Compound Library Sharing
March 20, 2014
- Galderma Files NDA for Cancer Odor Treatment
March 20, 2014
- Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
- Sanofi Settles Allegra Generic Suit with Elmed Eisai, Kobayashi Kako
March 19, 2014
- Daiichi Sankyo Files NDA for Methylene Blue for Methemoglobinemia
March 19, 2014
- Genzyme Asia Pacific Senior VP to Run Japan Operations
March 18, 2014
- Novartis Workers were Acting for Office of SIGN Trial Initiator Group: University of Tokyo
March 17, 2014
- Bayer Yakuhin Chairman Eiki to Step Down
March 17, 2014
- LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
- Nichi-Iko to Name Company Succeeded from Astellas “Nichi-Iko Pharma Tech”
March 14, 2014
- Takeda to Abolish CCO Post, Commercial Operations to Come Directly Under Weber’s Control
March 14, 2014
- Will Original Drug Makers Suddenly Embrace AGs? Comments of MHLW Official Could Spark Big Changes
March 14, 2014
- Otsuka to Disclose Patient-Level Clinical Trial Data
March 13, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…